{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-03T13:57:54.364553+00:00","company":{"ticker":"KYMR","cik":1815442,"company_name":"Kymera Therapeutics, Inc."},"pagination":{"limit":100,"returned":7,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"1b87ed59aea2753dc94652c67b9fce61bbff5e80","cik":1815442,"ticker":"KYMR","company_name":"Kymera Therapeutics, Inc.","filed_at":"2026-04-30T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the first quarter ended March 31, 2026","report_date":"2026-04-30","result_type":"reported_results","revenue_text":null},"claim":"Kymera Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2026.","evidence_excerpt":"On April 30, 2026, Kymera Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2026.","confidence":0.85,"filing_url":"https://secwatch.observer/filing/0001193125-26-193957","anchor_url":"https://secwatch.observer/filing/0001193125-26-193957#claim-1b87ed59aea2753dc94652c67b9fce61bbff5e80","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526193957/0001193125-26-193957-index.htm"},{"fact_type":"governance_change","fact_key":"6754406f86add6aa7f6bad4c28e28c66c7c2a2b6","cik":1815442,"ticker":"KYMR","company_name":"Kymera Therapeutics, Inc.","filed_at":"2026-03-27T23:59:59+00:00","payload":{"change_type":"bylaw_amendment","effective_date":"2026-03-25","item_codes_triggered":["5.03"],"summary_text":"Amended bylaws to designate federal district courts as exclusive forum for Securities Act and Exchange Act claims."},"claim":"Kymera Therapeutics, Inc.: Amended bylaws to designate federal district courts as exclusive forum for Securities Act and Exchange Act claims (effective 2026-03-25).","evidence_excerpt":"On March 25, 2026, the Board of Directors (the “Board”) of Kymera Therapeutics, Inc. (the “Company”) approved an amendment to the Company’s Second Amended and Restated Bylaws (the “Bylaw Amendment”), effective immediately, to designate the federal district courts of the United States as the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, or the respective rules and regulations promulgated thereunder, unless the Company consents in writing to the selection of an alternative forum.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-129170","anchor_url":"https://secwatch.observer/filing/0001193125-26-129170#claim-6754406f86add6aa7f6bad4c28e28c66c7c2a2b6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526129170/0001193125-26-129170-index.htm"},{"fact_type":"material_agreement","fact_key":"f687f47e3dbca8bac0145861e66bf96bf8e78879","cik":1815442,"ticker":"KYMR","company_name":"Kymera Therapeutics, Inc.","filed_at":"2026-02-26T23:59:59+00:00","payload":{"action":"termination","agreement_name":"Open Market Sale Agreement SM","agreement_type":"atm_program","counterparty":"Jefferies LLC","effective_date":"2026-02-26","item_codes_triggered":["1.02"],"value_text":null},"claim":"Kymera Therapeutics, Inc. terminated Open Market Sale Agreement SM with Jefferies LLC (effective 2026-02-26).","evidence_excerpt":"On February 26, 2026, Jefferies LLC (“Jefferies”) acknowledged and accepted the Company’s prior written notice to terminate the Open Market Sale Agreement SM , dated as of October 31, 2024, by and between the Company and Jefferies, effective immediately.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-073561","anchor_url":"https://secwatch.observer/filing/0001193125-26-073561#claim-f687f47e3dbca8bac0145861e66bf96bf8e78879","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526073561/0001193125-26-073561-index.htm"},{"fact_type":"material_agreement","fact_key":"7a56c9bb594b8e79b3d7374a41236e88bf5461a6","cik":1815442,"ticker":"KYMR","company_name":"Kymera Therapeutics, Inc.","filed_at":"2026-02-26T23:59:59+00:00","payload":{"action":"entry","agreement_name":"TD Cowen Sales Agreement","agreement_type":"atm_program","counterparty":"TD Securities (USA) LLC","effective_date":"2026-02-26","item_codes_triggered":["1.01"],"value_text":"up to $500,000,000"},"claim":"Kymera Therapeutics, Inc. entered into TD Cowen Sales Agreement with TD Securities (USA) LLC valued at up to $500,000,000 (effective 2026-02-26).","evidence_excerpt":"On February 26, 2026, Kymera Therapeutics, Inc. (the “Company”) entered into a Sales Agreement (the “TD Cowen Sales Agreement”), with TD Securities (USA) LLC (“TD Cowen”) with respect to an “at-the-market” offering program under which the Company may issue and sell, from time to time at the Company’s sole discretion, shares of the Company’s common stock, having an aggregate offering price of up to $500,000,000 (the “Shares”), through TD Cowen.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-073561","anchor_url":"https://secwatch.observer/filing/0001193125-26-073561#claim-7a56c9bb594b8e79b3d7374a41236e88bf5461a6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526073561/0001193125-26-073561-index.htm"},{"fact_type":"executive_change","fact_key":"67cbae0dc9","cik":1815442,"ticker":"KYMR","company_name":"Kymera Therapeutics, Inc.","filed_at":"2025-02-27T23:59:59+00:00","payload":{"action":"does not intend to stand for reelection","action_category":"departure","departure_tone":"routine","effective_date":null,"interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Leigh Morgan departed as Director at Kymera Therapeutics, Inc..","evidence_excerpt":"On February 24, Leigh Morgan, a member of the Board of Directors (the “Board”) of the Company, the Compensation and Talent Committee of the Board, and a member and chair of the Nominating and Corporate Governance Committee of the Board, informed the Company that she does not intend to stand for reelection at the Company’s 2025 annual meeting of shareholders.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-25-037588","anchor_url":"https://secwatch.observer/filing/0001193125-25-037588#claim-67cbae0dc9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312525037588/0001193125-25-037588-index.htm"},{"fact_type":"executive_change","fact_key":"f48f470034","cik":1815442,"ticker":"KYMR","company_name":"Kymera Therapeutics, Inc.","filed_at":"2024-06-20T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-06-18","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Joanna Horobin resigned as Director at Kymera Therapeutics, Inc..","evidence_excerpt":"On June 18, 2024, Joanna Horobin, M.B., Ch.B. a member of the Board of Directors (the “Board”) of Kymera Therapeutics, Inc. (the “Company”) and the Audit Committee of the Board (the “Audit Committee”) and Nominating and Corporate Governance Committee of the Board (the “Nominating and Corporate Governance Committee”), notified the Company of her resignation from the Board and all committees thereof, effective immediately.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-24-164550","anchor_url":"https://secwatch.observer/filing/0001193125-24-164550#claim-f48f470034","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312524164550/0001193125-24-164550-index.htm"},{"fact_type":"earnings_release","fact_key":"5f8d3f3e4c1b95f889416ff935a9dbd798a70e04","cik":1815442,"ticker":"KYMR","company_name":"Kymera Therapeutics, Inc.","filed_at":"2024-05-02T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the quarter ended March 31, 2024","report_date":"2024-05-02","result_type":"reported_results","revenue_text":null},"claim":"Kymera Therapeutics, Inc. reported financial results for the quarter ended March 31, 2024.","evidence_excerpt":"On May 2, 2024, Kymera Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2024.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0000950170-24-051566","anchor_url":"https://secwatch.observer/filing/0000950170-24-051566#claim-5f8d3f3e4c1b95f889416ff935a9dbd798a70e04","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1815442/000095017024051566/0000950170-24-051566-index.htm"}]}